A Phase 2 study evaluating the efficacy and safety of topical diacerein 1% compared with placebo in patients with Epidermolysis Bullosa Simplex (EBS).

Trial Profile

A Phase 2 study evaluating the efficacy and safety of topical diacerein 1% compared with placebo in patients with Epidermolysis Bullosa Simplex (EBS).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Diacerein (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Mar 2017 According to a Castle Creek Pharmaceuticals media release, results from the study have been presented in a late-breaker session at the American Academy of Dermatology Annual Meeting.
    • 06 Mar 2017 Results published in a Castle Creek Pharmaceuticals media release.
    • 14 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top